CoChat

Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus

Open access
Berry, Jody D, Jones, Steven, Drebot, Michael A, Andonov, Anton, Sabara, Marta, Yuan, Xin Y, Weingartl, Hana, Fernando, Lisa, Marszal, Peter, Gren, Jason, Nicolas, Brigitte, Andonova, Maya, Ranada, Francesca, Gubbins, Michael J, Ball, T.Blake, Kitching, Paul, Li, Yan, Kabani, Amin, Plummer, Frank · 2004 · Journal of Virological Methods
Cited by 111

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

There is a global need to elucidate protective antigens expressed by the SARS-coronavirus (SARS-CoV). Monoclonal antibody reagents that recognise specific antigens on SARS-CoV are needed urgently. In this report, the development and immunochemical characterisation of a panel of murine monoclonal antibodies (mAbs) against the SARS-CoV is presented, based upon their specificity, binding requirements, and biological activity. Initial screening by ELISA, using highly purified virus as the coating antigen, resulted in the selection of 103 mAbs to the SARS virus. Subsequent screening steps reduced this panel to seventeen IgG mAbs. A single mAb, F26G15, is specific for the nucleoprotein as seen in Western immunoblot while five other mAbs react with the Spike protein. Two of these Spike-specific mAbs demonstrate the ability to neutralise SARS-CoV in vitro while another four Western immunoblot-negative mAbs also neutralise the virus. The utility of these mAbs for diagnostic development is demonstrated. Antibody from convalescent SARS patients, but not normal human serum, is also shown to specifically compete off binding of mAbs to whole SARS-CoV. These studies highlight the importance of using standardised assays and reagents. These mAbs will be useful for the development of diagnostic tests, studies of SARS-CoV pathogenesis and vaccine development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jviromet.2004.04.009

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 111

Metadata

Authors
Berry, J. D., Jones, S., Drebot, M. A., Andonov, A., Sabara, M., Yuan, X. Y., Weingartl, H., Fernando, L., Marszal, P., Gren, J., Nicolas, B., Andonova, M., Ranada, F., Gubbins, M. J., Ball, T. B., Kitching, P., Li, Y., Kabani, A., & Plummer, F.
Venue
Journal of Virological Methods
Publisher
Elsevier BV
Published
2004-09
Volume
120
Issue
1
Pages
87-96
ISSN
0166-0934 (ISSN-L)
OpenAlex
W2080708468
Cited by
111
References
1
FWCI
7.20
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus. https://app.cochat.ai/papers/10.1016/j.jviromet.2004.04.009
The paper
Berry, J. D., Jones, S., Drebot, M. A., Andonov, A., Sabara, M., Yuan, X. Y., Weingartl, H., Fernando, L., Marszal, P., Gren, J., Nicolas, B., Andonova, M., Ranada, F., Gubbins, M. J., Ball, T. B., Kitching, P., Li, Y., Kabani, A., & Plummer, F. (2004). Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus. Journal of Virological Methods. https://doi.org/10.1016/j.jviromet.2004.04.009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.